Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) is focused on discovering and developing direct-acting antivirals to treat infections that affect a significant number of patients globally. The company has four product candidates with limited therapeutic options in development. Biota is currently enrolling patients for the phase IIb SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. For more information, visit the company’s website at www.biotapharma.com.